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Abstract
Background and Aim: Metabolic acidosis is common in patients with chronic kidney disease and is associated with
increased mortality in hemodialysis patients. However, this relationship has not yet been determined in peritoneal
dialysis (PD) patients.
Methods: This prospective observational study included a total of 441 incident patients who started PD between
January 2000 and December 2005. Using time-averaged serum bicarbonate (TA-Bic) levels, we aimed to investigate
whether a low serum bicarbonate concentration can predict mortality in these patients.
Results: Among the baseline parameters, serum bicarbonate level was positively associated with hemoglobin level
and residual glomerular filtration rate (GFR), while it was negatively associated with albumin, C-reactive protein
(CRP) levels, peritoneal Kt/V urea, and normalized protein catabolic rate (nPCR) in a multivariable linear regression
analysis. During a median follow-up of 34.8 months, 149 deaths were recorded. After adjustment for age, diabetes,
coronary artery disease, serum albumin, ferritin, CRP, residual GFR, peritoneal Kt/V urea, nPCR, and percentage of
lean body mass, TA-Bic level was associated with a significantly decreased risk of mortality (HR per 1 mEq/L
increase, 0.83; 95% CI, 0.76-0.91; p < 0.001). In addition, compared to patients with a TA-Bic level of 24-26 mEq/L,
those with a TA-Bic level < 22 and between 22-24 mEq/L conferred a 13.10- and 2.13-fold increased risk of death,
respectively.
Conclusions: This study showed that a low serum bicarbonate concentration is an independent risk factor for
mortality in PD patients. This relationship between low bicarbonate levels and adverse outcome could be related to
enhanced inflammation and a more rapid loss of RRF associated with metabolic acidosis. Large randomized clinical
trials to correct acidosis are warranted to confirm our findings.
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Introduction
A low serum bicarbonate concentration, manifested as an
important clinical disturbance of metabolic acidosis, is common
in end-stage renal disease (ESRD) and is believed to be an
important cause of many deleterious metabolic consequences
including protein-energy wasting, inflammation, bone disease,
and disturbance in endocrine function [1–5]. The unfavorable
effects of metabolic acidosis can explain the increased
mortality in patients undergoing maintenance hemodialysis
(HD), but the underlying mechanisms are still in need of
clarification. In addition, the optimal bicarbonate level to avoid
adverse clinical outcomes is largely unknown [6–9].
Along with HD, peritoneal dialysis (PD) is an established
treatment modality in ESRD and approximately 150,000
patients worldwide are being maintained on PD [10]. Given the
continuous provision of dialysis treatment with PD, it can be
presumed that PD may be more effective in correcting
metabolic acidosis than HD; thus, the effect of metabolic
acidosis on clinical outcomes may differ between the two
dialysis modalities. However, few studies have examined the
relationship between serum bicarbonate level and risk of death
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in PD patients. Therefore, the intent of this study was to
investigate whether low serum bicarbonate levels can predict
mortality in a large prospective cohort of incident patients
undergoing PD.
Methods
Ethics statement
The study was carried out in accordance with the Declaration
of Helsinki and approved by the Institutional Review Board of
Ilsan Hospital Clinical Trial Center. We obtained informed
written consent from all participants involved in our study.
Patients
The study population included 549 ESRD patients who
started PD at Yonsei University Severance Hospital or NHIS
Ilsan hospital between January 2000 and December 2005. All
patients underwent urea kinetic studies including residual renal
function (RRF) within three months of PD initiation. We
excluded patients < 18 years of age at initiation of PD, patients
that had less than 6 months of follow-up, and patients that had
been on HD or received a kidney transplant before the initiation
of PD. Patients that recovered kidney function or started PD for
other reasons, such as acute renal failure or congestive heart
failure, were also excluded from the analysis. Therefore, this
prospective observational study included a total of 441 incident
patients (Figure 1).
Data collection
Demographic and clinical data were collected at the
beginning of PD. These included age, gender, body mass
index (BMI) calculated as weight/(height)2, cause of ESRD,
prevalence of diabetes and coronary artery disease (CAD).
Laboratory data obtained at the time of dialysis adequacy
measurement were considered baseline values and included
serum bicarbonate concentrations, blood urea nitrogen, serum
creatinine, total cholesterol, serum albumin, serum C-reactive
protein (CRP) levels, Kt/V urea, percentage of lean body mass
(%LBM), normalized protein catabolic rate (nPCR), and
residual glomerular filtration rate (GFR). Residual GFR was
calculated as the average urea and creatinine clearance from a
24-h urine collection [11]. Serum total CO2, which is generally
used as an indirect measure of serum bicarbonate
concentration [2], was measured by an electrode-based
method (UniCel DXC 800; Beckman Coulter, Inc., CA, USA)
and recorded longitudinally throughout the follow-up period.
Time-averaged serum bicarbonate (TA-Bic) was calculated as
an average of the mean of bicarbonate measurements every 3-
month period.
Study outcomes
The study participants were followed until December 31,
2011. The primary outcome parameter was all-cause and
cardiovascular mortality.
Statistical analysis
All values are expressed as the mean ± standard deviation
or percentages. Statistical analyses were performed using
SPSS for Windows version 13.0 (SPSS, Inc., Chicago, IL,
USA). Data were analyzed using Student’s t–test and the Chi-
square test, and ANOVA was used for multiple comparisons.
The Kolmogorov-Smirnov test was used to determine the
normality of the distribution of parameters. If data did not show
a normal distribution, they were expressed as the median and
interquartile range (or after log-transformation) and were
compared using the Mann–Whitney test or Kruskal–Wallis test.
The relationships between serum bicarbonate and continuous
variables were examined by Pearson’s correlation coefficient,
and categorical variables were examined using Spearman’s R
test. Multiple linear regression analysis was performed to
identify the determinants of serum bicarbonate levels. Survival
rate was compared among 3 groups based on TA-Bic levels (<
22, 22 to 24, and ≥ 24 mEq/L) using the Kaplan-Meier method
and the log-rank test. Data for switch to HD, kidney
transplantation, and loss to follow-up were censored in the
analysis. Patients who died within the first 3 months after
converting to HD or receiving a kidney graft were considered
Figure 1.  Flow chart of participants in the cohort.  PD, peritoneal diaysis; HD, hemodialysis; KT, kidney transplant.
doi: 10.1371/journal.pone.0082912.g001
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deaths related to PD. To determine risk factors for mortality,
multivariate Cox regression was performed, and all significant
covariates from the univariate analysis were included. The
results are expressed as a hazard ratio (HR) and 95%
confidence interval (CI). A p–value less than 0.05 was
considered statistically significant.
Results
Patient characteristics
The mean age of the patients was 59.2 years (range, 22 to
85 years), 54.4% were males, and patients were on PD for a
mean duration of 43.2 months (range, 6 to 142 months). The
prevalence of diabetes and CAD was 51.5% and 15.9%,
respectively. The mean TA-Bic level was 25.9 ± 2.4 mEq/L
(median, 25.8 mEq/L; range, 16.6 to 33.9 mEq/L). Table 1
details the baseline characteristics of the 441 patients
categorized into 5 groups by TA-Bic level: < 22 mEq/L, ≥ 28
mEq/L, and every 2.0 mEq/L increment of bicarbonate in
between. Serum hemoglobin (p for trend < 0.001), total
cholesterol concentrations (p for trend = 0.024), and residual
GFR (p for trend = 0.015) were higher at higher TA-Bic level,
whereas serum albumin (p for trend = 0.001), peritoneal Kt/V
urea (p for trend < 0.001), and serum CRP levels (p for trend <
0.001) were lower.
Factors associated with baseline serum bicarbonate
Correlation analyses were performed to identify factors
associated with baseline serum bicarbonate level (Table 2).
There was no correlation between age, BMI, presence of
preexisting CAD, serum ferritin, total Kt/V urea, %LBM, and
serum bicarbonate. In contrast, baseline serum bicarbonate
level positively correlated with male gender (ρ = 0.127; p =
0.007), presence of diabetes (ρ = 0.125; p = 0.009),
hemoglobin (ρ = 0.226; p < 0.001), total cholesterol levels (ρ =
0.130; p = 0.006), and residual GFR (ρ = 0.158; p = 0.001),
whereas it inversely correlated with serum albumin (ρ = -0.227;
p < 0.001), serum CRP levels (ρ = -0.182; p < 0.001),
peritoneal Kt/V urea (ρ = -0.267; p < 0.001), and nPCR (ρ =
-0.177; p < 0.001). Multivariate linear regression analysis
adjusted for these factors revealed that serum hemoglobin (β =
0.153; p = 0.001), serum albumin (β = -0.275; p < 0.001), CRP
levels (β = -0.148; p = 0.002), residual GFR (β = 0.118; p =
0.027), peritoneal Kt/V urea (β = -0.120; p = 0.028), and nPCR
(β = -0.121; p = 0.018) were independently associated with
baseline serum bicarbonate (Table 2).
Metabolic acidosis as a predictor of mortality
During follow-up, 149 deaths were recorded, and the median
survival period was 34.8 months (range, 6.0 to 142.2 months).
Infection (37.6%) was the most common cause of death in this
study, followed by cardiovascular disease (36.2%).
In the unadjusted Cox proportional hazards models, TA-Bic
level significantly predicted all-cause mortality (HR per 1 mEq/L
increase, 0.88; 95% CI, 0.81-0.95; p = 0.001). A Kaplan-Meier
plot also showed that time to death was significantly longer in
patients with a higher TA-Bic level compared to patients with a
TA-Bic level < 22 mEq/L (Figure 2). In addition, age, diabetes,
preexisting CAD, serum albumin, ferritin, CRP, residual GFR,
peritoneal Kt/V urea, nPCR, and %LBM were revealed as
predictors of mortality. In the multivariable analysis after
adjustment of these factors, increased TA-Bic level was
associated with a significantly decreased risk of death (HR per
1 mEq/L increase, 0.83; 95% CI, 0.76-0.91; p < 0.001) (Table
Table 1. Baseline characteristics of the study subjects stratified by time-averaged serum bicarbonate.
 Time-averaged serum bicarbonate (mEq/L; Number of subjects)  
 <22 (n=18) 22 to <24 (n=83) 24 to <26 (n=127) 26 to <28 (n=128) ≥28 (n=85) p for trend
Age (years) 64.1 ± 11.5 57.4 ± 14.0 57.2 ± 14.0 60.7 ± 13.7 60.8 ± 13.5 0.182
Gender (Male) 11 (61.1) 41 (49.4) 69 (54.3) 69 (53.9) 50 (58.8) 0.463
Body mass index (kg/m2) 21.6 ± 2.6 22.7 ± 3.3 23.6 ± 11.5 22.6 ± 2.9 22.5 ± 3.3 0.820
Presence of diabetes mellitus 8 (44.4) 38 (45.8) 62 (48.8) 71 (55.5) 48 (56.5) 0.076
Presence of coronary artery disease 3 (16.7) 10 (12.0) 14 (11.0) 28 (21.9) 15 (17.6) 0.113
Laboratory findings       
Hemoglobin (g/dL) 10.4 ± 1.5 10.3 ± 1.6 10.8 ± 1.5 11.0 ± 1.5 11.4 ± 1.3 <0.001
Serum albumin (g/dL) 3.2 ± 0.6 3.2 ± 0.5 3.3 ± 0.5 3.1 ± 0.5 3.0 ± 0.6 <0.001
Total cholesterol (mg/dL) 170.0 [105-250] 177.0 [6-383] 183.0 [94-273] 181.0 [66-451] 178.0 [95-334] 0.024
Serum ferritin (ng/mL) 286 [55-1429] 270.2 [15-1693] 174.3 [7-1711] 124.7 [14-1680] 157.6 [21-1373] 0.062
CRP (mg/dL) 0.3 [0.01-8.1] 0.2 [0.01-36.2] 0.1 [0.01-36.3] 0.1 [0.01-9.1] 0.02 [0.01-4.7] <0.001
Residual GFR (mL/min/1.73m2) 3.1 [0.7-11.2] 5.1 [0.5-15.8] 5.4 [0.6-18.8] 5.5 [0.6-26.9] 5.9 [0.6-36.9] 0.015
Total Kt/Vurea 2.3 ± 0.6 2.7 ± 0.9 2.7 ± 0.8 2.6 ± 0.9 2.4 ± 0.6 0.106
Peritoneal Kt/V urea 1.6 ± 0.6 1.6 ± 0.5 1.6 ± 0.6 1.4 ± 0.5 1.2 ± 0.5 <0.001
nPCR (g/Kg/day) 0.8 ± 0.2 1.0 ± 0.2 1.0 ± 0.3 1.0 ± 0.3 1.0 ± 0.2 0.533
Lean body mass (% body weight) 55.3 ± 13.4 66.6 ± 14.2 65.8 ± 13.6 63.1 ± 12.7 63.5 ± 14.9 0.931
Values for categorical variables are given as number (percentage); values for continuous variables are given as mean ± standard deviation or median [interquartile range].
CRP, C-reactive protein; GFR, glomerular filtration rate; nPCR, normalized protein catabolic rate.
doi: 10.1371/journal.pone.0082912.t001
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3). A similar association was observed between TA-Bic level
and cardiovascular mortality (Figure 2 and Table 3); however,
there was no significant relationship between TA-Bic level and
infection-related death (data not shown).
We also conducted a separate multivariate analysis in which
TA-Bic levels were categorized into 5 groups as presented in
Table 1. Compared to patients with a TA-Bic level of 24-26
mEq/L, patients with a TA-Bic level < 22 mEq/L and 22-24
mEq/L conferred a 13.10- and 2.13-fold increased risk of all-
cause mortality, respectively. HRs for cardiovascular death
were 7.10 and 2.73 in patients with a TA-Bic level < 22 mEq/L
and 22-24 mEq/L versus those with a TA-Bic level of 24-26
mEq/L. However, no further survival advantage was observed
with TA-Bic level greater than 26 mEq/L (Figure 3).
Discussion
In this study, we aimed to delineate the relationship between
serum bicarbonate levels and mortality in our ESRD cohort of
patients with PD. We showed that serum bicarbonate level
exhibited a significant inverse association with serum albumin
and CRP levels, while it positively correlated with RRF. In
addition, low TA-Bic level independently predicted all-cause
and cardiovascular mortality in these patients, suggesting that
metabolic acidosis exerts a detrimental effect; thus, patients
with a low bicarbonate level should be considered for proper
treatment even though they are receiving dialysis therapy.
Unlike conventional HD, PD provides continuous dialysis,
which leads to the assumption that metabolic acidosis is
uncommon in patients with PD. To date, the prevalence of
metabolic acidosis in PD patients has not been fully explored,
Table 2. Univariate and multivariate associations between baseline serum bicarbonate level and patient characteristics.
 Univariate  Multivariate
 ρ p  β p
Age (years) 0.049 0.303  － －
Gender (Male) 0.127 0.007  0.040 0.413
Body mass index (kg/m2) -0.020 0.677  — －
Presence of diabetes 0.125 0.009  0.015 0.753
Presence of coronary artery disease 0.086 0.071  — －
Hemoglobin (g/dL) 0.226 <0.001  0.153 0.001
Serum albumin (g/dL) -0.227 <0.001  -0.275 <0.001
Total cholesterol (mg/dL)a 0.130 0.006  0.079 0.098
Ferritin (ng/mL)a -0.082 0.086  — —
CRP (mg/dL)a -0.182 <0.001  -0.148 0.002
Residual GFR (mL/min/1.73m2)a 0.158 0.001  0.118 0.027
Total Kt/Vurea -0.069 0.151    
Peritoneal Kt/V urea -0.267 <0.001  -0.120 0.028
nPCR (g/Kg/day) -0.177 <0.001  -0.121 0.018
Lean body mass (% body weight) -0.028 0.868  — －
CRP, C-reactive protein; GFR, glomerular filtration rate; nPCR, normalized protein catabolic rate. aData for total cholesterol, ferritin, CRP, and residual GFR were log
transformed.
doi: 10.1371/journal.pone.0082912.t002
Figure 2.  Kaplan-Meier plots for all-cause (right) and cardiovascular (left) mortality based on the level of time-averaged
serum bicarbonate (TA-Bic).  
doi: 10.1371/journal.pone.0082912.g002
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and several studies have reported that the proportion of
patients with serum bicarbonate < 22 mEq/L varies widely from
10 to 25% [6,12–14]. Of note, most previous studies conducted
cross-sectional surveys using a single measurement of serum
bicarbonate concentration [12–14]. Given that such a value
measured at a single specific time-point does not represent
acid-base state during the entire period of dialysis, TA-Bic is a
more reliable parameter to reflect acidosis. In fact, in this study,
there were only 4.1% of patients with a TA-Bic level < 22
mEq/L, while 14.5% of patients had a serum bicarbonate level
< 22 mEq/L at the time of PD initiation. Surprisingly, a recent
large cohort study using the DaVita database reported that
25% of patients had a TA-Bic level < 22 mEq/L, which was
unexpectedly high [6]. The authors postulated that the delayed
measurements performed in samples shipped overnight to a
central laboratory might be responsible for the higher
prevalence of low serum bicarbonate level in their study. It
should be noted that artificial reduction in the total CO2
concentration might result from increased lactic acid production
due to delays in the centrifugation of blood and in analysis [15].
Thus, the presence of metabolic acidosis should be verified by
on-site measurements. To minimize biased results, the two
centers in the present study used the same analyzer to
measure biochemical parameters including bicarbonate level,
and all samples were analyzed within 4 hours after blood
sampling.
Our findings provide concrete evidence that low serum
bicarbonate level is associated with adverse outcome in PD
patients as well as in HD patients and chronic kidney disease
patients prior to dialysis therapy [6–9,16]. The robust analyses
of our study clearly show that low serum bicarbonate level is an
independent predictor of mortality in the multivariate Cox
Table 3. Cox regression analysis for all-cause and cardiovascular mortality.
 All-cause mortality  Cardiovascular mortality
 Univariate  Multivariate  Univariate  Multivariate
 HR (95% CI) p  HR (95% CI) p  HR (95% CI) p  HR (95% CI) p
Age (years) 1.08 (1.06-1.10) <0.001  1.07 (1.04-1.09) <0.001  1.05 (1.03-1.08) <0.001  1.04 (1.01-1.07) 0.004
Gender (Male) 1.25 (0.90-1.73) 0.183  — — —  1.48 (0.85-2.56) 0.164  — — —
Body mass index (kg/m2) 1.00 (0.98-1.02) 0.971  — — —  0.98 (0.92-1.05) 0.627  — — —
Presence of diabetes 1.82 (1.31-2.54) <0.001  1.59 (1.07-2.34) 0.022  1.83 (1.05-3.17) 0.032  1.28 (0.69-2.37) 0.433
Presence of coronary artery disease 2.29 (1.55-3.39) <0.001  1.24 (0.80-1.93) 0.332  6.35 (3.63-11.13) <0.001  4.08 (2.23-7.46) <0.001
Hemoglobin (g/dL) 0.92 (0.82-1.02) 0.115  — — —  0.91 (0.77-1.09) 0.310  — — —
Serum albumin (g/dL) 0.28 (0.21-0.38) <0.001  0.36 (0.25-0.52) <0.001  0.34 (0.21-0.57) <0.001  0.36 (0.20-0.64) <0.001
Total cholesterol (mg/dL)a 0.85 (0.26-2.82) 0.848  — — —  0.44 (0.05-4.26) 0.481  — — —
Serum ferritin (ng/mL)a 2.94 (2.03-4.26) <0.001  1.25 (0.85-1.83) 0.264  2.60 (1.40-4.81) 0.002  1.39 (0.73-2.63) 0.318
CRP (mg/dL)a 1.75 (1.39-2.19) <0.001  1.15 (0.90-1.47) 0.262  1.43 (0.99-2.08) 0.058  — — —
TA-Bic (mEq/L) 0.88 (0.81-0.95) 0.001  0.83 (0.76-0.91) <0.001  0.81 (0.71-0.92) 0.001  0.78 (0.69-0.88) <0.001
Residual GFR (mL/min/1.73m2)a 0.28 (0.18-0.43) <0.001  0.43 (0.22-0.84) 0.013  0.25 (0.13-0.52) <0.001  0.49 (0.22-1.09) 0.077
Peritoneal Kt/Vurea 1.40 (1.05-1.86) 0.021  0.85 (0.57-1.28) 0.850  1.28 (0.80-2.04) 0.303  — — —
nPCR (g/Kg/day) 0.18 (0.09-0.38) <0.001  0.62 (0.38-1.79) 0.820  0.22 (0.07-0.72) 0.012  0.87 (0.28-2.66) 0.804
Lean body mass (% body weight) 0.96 (0.94-0.97) <0.001  1.00 (0.98-1.02) 0.969  0.97 (0.95-0.99) 0.001  1.01 (0.98-1.04) 0.391
CRP, C-reactive protein; TA-Bic, time-averaged serum bicarbonate; GFR, glomerular filtration rate; nPCR, normalized protein catabolic rate, HR, hazard ratio; CI, confidence
interval. aData for total cholesterol, ferritin, CRP, and residual GFR were log transformed.
doi: 10.1371/journal.pone.0082912.t003
Figure 3.  Hazard ratios for all-cause (right) and cardiovascular (left) mortality in each of the five time-averaged serum
bicarbonate (TA-Bic) subgroups.  Error bars indicate 95% confidence intervals for unadjusted and adjusted models. The
subgroup with TA-Bic levels of 24-26 mEq/L was the reference group in all models.
doi: 10.1371/journal.pone.0082912.g003
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proportional hazards model adjusted for potentially multiple
confounding covariates such as age, comorbidities, serum
albumin, ferritin and CRP levels, RRF, Kt/V urea, nPCR, and
%LBM. In addition, patients with a TA-Bic levels < 22 mEq/L
and 22 to < 24 mEq/L had adjusted hazards ratios for all-cause
mortality of 13.10 and 2.13, respectively, compared to
reference patients with a TA-Bic level between 24 and 26
mEq/L. Relevant to our finding is a recent observation by
Vashistha et al. [6], showing that TA-Bic levels < 19 or 21 to <
22 mEq/L were associated with an 18% and 13% higher risk of
death in PD patients, respectively (reference group: TA-Bic 24
to < 25 mEq/L).
However, there is no consensus about the optimal
bicarbonate level in ESRD patients, and it is also uncertain
whether target serum bicarbonate level should be
individualized by dialysis modality. In an analysis of 7,140 HD
patients based on data from the Dialysis Outcomes and
Practice Pattern Study, the lowest risk for mortality was
associated with midweek pre-dialysis bicarbonate levels
between 20 and 21 mEq/L, while an increased risk was
observed in patients with high (> 27 mEq/L) or low (< 17
mEq/L) bicarbonate levels [7]. Another study of 56,385 HD
patients using the DaVita database showed a reverse J-shaped
pattern between serum bicarbonate and mortality, where serum
bicarbonate levels > 22 mEq/L were associated with lower
mortality risk. However, bicarbonate levels below this measure
showed a consistently increased risk [8]. Using the same
database, a recent study by Vashistha et al. [6] recruited the
largest cohort to date and obtained a similar result. Taken
together, among patients treated with HD, a low pre-dialysis
serum bicarbonate level, particularly < 22 mEq/L, appears to
correlate with poor survival. In keeping with these findings,
clinical practice guidelines from the National Kidney Foundation
Disease Outcomes Quality Initiative recommend a serum
bicarbonate level ≥ 22 mEq/L, irrespective of dialysis modality
[17,18].
Nevertheless, there is a lack of compelling evidence about
whether serum bicarbonate level should be maintained at > 22
mEq/L in patients with PD. Only two studies including ours
have addressed this issue in the PD population and have
shown conflicting results. In the aforementioned study by
Vashistha et al. [6], they extended the cohort to PD patients
and found that TA-Bic levels with 22 to < 24 mEq/L exhibited a
comparable risk of mortality compared to TA-Bic levels ≥ 24
mEq/L. In contrast, we showed that TA-Bic levels with 22 to <
24 mEq/L were associated with a significantly higher mortality
risk than TA-Bic levels ≥ 24 mEq/L (Figure 2 and 3). The
observational nature of our study does not fully explain this
discrepancy, but it is possible that a relatively low proportion of
patients with TA-Bic levels < 24 mEq/L led to the biased
results. However, it should be noted that, as previously
mentioned, delayed sample analysis may have falsely
decreased bicarbonate levels in the study by Vashistha et al.
[6]; thus, their findings should be interpreted with caution.
Interestingly, the United Kingdom Renal Association
recommends serum bicarbonate levels to be within the normal
range for PD patients but provides greater latitude for HD
patients (target pre-dialysis serum bicarbonate levels 18–24
mEq/L) [19,20]. The guidelines suggest a higher threshold of
bicarbonate in PD patients than in HD patients. A rationale for
this can be provided by two randomized controlled trials
indicating that oral bicarbonate supplement or dialysis fluid with
a 40 mmol buffer capacity significantly improved nutritional
status compared to a placebo group, although the mean
bicarbonate levels in patients treated with placebo were 24.7
and 23.0 mEq/L in the two studies, respectively [21,22]. Our
finding supports the target serum bicarbonate levels in PD
patients recommended by the recent UK guidelines.
The underlying mechanisms for increased mortality in PD
patients with lower serum bicarbonate are unclear. The
possible mechanisms include chronic inflammation [23–25] and
loss of RRF [26–28] which have been established to be a
powerful predictor of mortality in patients on dialysis. In our
study, serum bicarbonate level was inversely associated with
serum CRP levels, whereas it positively correlated with RRF,
therefore it is postulated that acidosis per se could be
worsened by inflammation or a more rapid loss of RRF. On the
other hand, we found that serum bicarbonate level negatively
correlated with serum albumin concentration as well as nPCR,
but was not related to other nutritional parameters such as
BMI, serum total cholesterol concentration, or %LBM. These
inconsistent results on relationship between bicarbonate level
and various nutritional parameters make it difficult to conclude
that such a negative correlation between serum bicarbonate
level and serum albumin found in our study is a reflection of
increased protein intake, which will also lead to a better
nutritional status. There are, however, controversial opinions
about the effect of serum bicarbonate on nutrition. Good dietary
intake is usually accompanied by high protein intake, which
increases acid load and can be a cause of acidosis in uremic
patients [3,7,14,23]. Conversely, metabolic acidosis per se can
have a negative impact on nutritional status including increased
proteolysis, decreased protein synthesis, endocrine
abnormalities including insulin resistance, and inflammation
[1–4,29–33]. More randomized, controlled trials are required to
explore if interventions to correct metabolic acidosis can
improve hard clinical outcomes such as mortality, and to clarify
if such an improvement is mediated through the attenuation of
inflammation and malnutrition.
There are several limitations in the present study. First, this
is an observational study with a relatively small sample size.
Hence, causality of our findings needs further confirmation.
Second, it is possible that more sick patients were included in
the group of TA-Bic < 22 mEq/L. We tried to minimize risk of
inclusion of such more seriously ill patients at the initiation of
PD by extending follow-up period up to 6 months. In fact, most
epidemiologic studies follow 90-day rule for inclusion of
incident-based patients, meaning that patients must have
survived the first 90 days on dialysis to be eligible for analysis
[34]. Nevertheless, we could not entirely exclude possibility that
patients with TA-Bic < 22 mEq/L might be in more seriously ill
condition. Third, other data representing overall nutritional
status such as subjective global assessment, anthropometry,
and dietary protein intake were not available for the analysis.
Importantly, a low serum bicarbonate level in this study may
not be diagnostic of metabolic acidosis, because it represents
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the state of low arterial pH (acidemia) and reduced serum
bicarbonate concentration, accompanied by decreased PCO2.
Unfortunately, data of arterial gas analyses such as arterial pH
and PCO2 were unavailable in our study, thus it is uncertain
whether a low serum bicarbonate level is associated with
combined acidemia or not. However, given the loss of buffering
capacity by the kidney in ESRD patients, they are more likely to
have metabolic acidosis than respiratory alkalosis, which is
another clinical condition that causes decreased bicarbonate
level. Despite these limitations, we adjusted various factors
associated with nutritional status, inflammation, and RRF and
found an adverse effect of a low serum bicarbonate level on
clinical outcome.
Conclusion
This study showed that a low serum bicarbonate level was
an independent risk factor for mortality in PD patients. The
relationship between low bicarbonate levels and adverse
outcome may be related to enhanced inflammation and a more
rapid loss of RRF associated with metabolic acidosis. Large
randomized clinical trials to correct acidosis are warranted to
confirm our findings.
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